Cardiovascular impact of the autonomic neuropathy of diabetes mellitus;Impacto cardiovascular da neuropatia autonômica do diabetes mellitus

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 2, 2007, Pages 232-243

  Schmid, Helena ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b NONE   (Brazil)

Author keywords

Cardiovascular autonomic neuropathy; Cardiovascular disease; Diabetes mellitus

Indexed keywords

EID: 34248575372     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302007000200012     Document Type: Review

References (60)

1. Neumann C, Branchtein L, Schmid H. Severe autonomic neuropathy how many symptoms? Diabetes Care 1995;18(1):133-4.
2. Schmid H, Forman L, Sherman P, Stevens M. Heterogeneous cardiac sympathetic denervation and decreased myocardial nerve growth factor in streptozotocin diabetic rats implications for cardiac sympathetic dysinnervation complicating diabetes. Diabetes 1999;48:603-8.
3. Neumann C, Schmid H. Relationship between the degree of cardiovascular autonomic dysfunction and symptoms of neuropathy and other complications of diabetes mellitus. Braz J Med Biol Res 1995;28:751-7.
4. Neumann C, Schmid H. Standardization of a computerized method for calculating autonomic function tests responses in healthy; subjects and patients with diabetes mellitus. Braz J Med Biol Res 1997;30:197-205.
5. Pop-Busui R, Kirkwood I, Schmid H, Marinescu V, Schroeder J, Larkin D, et al. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol 2004;44(12):2368-74.
6. Schmid H, Schaan B, Cecconello F, Maestri T, Neumann C. Proliferative diabetic retinopathy is related to cardiovascular autonomic neuropathy in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1995;29(3):163-8.
7. Neumann C, Martinez D, Schmid H. Nocturnal oxygen desaturation in diabetic patients with severe autonomic neuropathy. Diabetes Res Clin Pract 1995;28(2):97-102.
8. Schaan BD, Lacchini S, Bertoluci M, Irigoyen MC, Machado UF, Schmid H. Increased renal GLUT 1 abundance and urinary TGFβ1 in streptozotocin- induced diabetic rats implications for the development of nephropathy complicating diabetes. Horm Metab Res 2001;33:664-9.
9. D'Agord Schaan B, Lacchini S, Bertoluci MC, Irigoyen MC, Machado UF, Schmid H. Impact of renal denervation on renal content of GLUT1, albuminuria and urinary TGF-beta1 in streptozotocin-induced diabetic rats. Auton Neurosci 2003;104(2):88-94.
10. Schaan BD, Irigoyen MC, Lacchini S, Moreira ED, Schmid H, Machado UF. Sympathetic modulation of the renal glucose transporter GLUT2 in diabetic rats. Auton Neurosci 2005;117(1):54-61.
11. Schaan BD, Dall'Ago P, Maeda CY, Ferlin E, Fernandes TG, Schmid H, et al. Relationship between cardiovascular dysfunction and hyperglycemia in streptozotocin-induced diabetes in rats. Braz J Med Biol Res 2004;37(12):1895-902.
12. Schaan BD, Maeda CY, Timm HB, Medeiros S, Moraes RS, Ferlin E, et al. Time course of changes in heart rate and blood pressure variability in rats with streptozotocin-induced diabetes treated with insulin. Braz J Med Biol Res 1997;30(9):1081-6.
13. Ferreira A. Uso da estesiometria e biotesiometria para o diagnóstico de polineuropatia periférica do diabete melito e do pé diabético em risco de ulceração neuropática. Dissertação (Pós- graduação em Medicina, Clínica Médica). Universidade Federal do Rio Grande do Sul, 1997.
14. American Diabetes Association, American Academy of Neurology Report and recommendations of the San Antonio Conference on Diabetic Neuropathy Consensus Statement. Diabetes Care 1988;11:592-7.
15. American Diabetes Association and American Academy of Neurology. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Diabetes Care 1992;15:1080-107.
16. Thomas PK. Classification of the diabetic neuropathies. In: Gries FA, Cameron NE, Low PA, Ziegler D. Textbook of Diabetic Neuropathy. Georg Thieme Verlag, 2003.
17. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004;27:1458-86.
18. Vinik AI, Maser RE, Michell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26(5):1553-79.
19. Meyer C, Grossmann R, Mitrakou A, Mahler R, Veneman T, Gerich J, et al. Effects of autonomic neuropathy on counter-regulation and awareness of hypoglycemia in type 1 diabetic patients. Diabetes Care 1988;21:1960-6.
20. Shaw JE, Zinmet PZ, Gries FA, Ziegler D. Epidemiology of diabetic neuropathy. In: Gries FA, Cameron NE, Low PA, Ziegler D. Textbook of Diabetic Neuropathy. Georg Thieme Verlag, 2003.
21. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
22. Feldman EL, Stevens MJ, Greene DA. Pathogenesis of diabetic neuropathy. Clin Neurosci 1997;4(6):365-70.
23. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992;15:1835-43.
24. Greene DA, Stevens MJ, Obrosova I, Feldman EL. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur J Pharmacol 1999;375(1-3):217-25.
25. Dyck PJ, Lais A, Karnes JL, O'Brien P, Rizza R. Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986;19(5):425-39.
26. Stevens MJ, Feldman EL, Greene DA. The aetiology of diabetic neuropathy the combined roles of metabolic and vascular defects. Diabet Med 1995;12(7):566-79.
27. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
28. Feldman EL. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J Clin Invest 2003;111:431-3.
29. Hellweg R, Hartung HD. Endogenous levels of growth factor are altered in experimental diabetes mellitus: a possible role of NGF on the pathogenesis of diabetes neuropathy. J Neurosci Res 1990;26:258-67.
30. Nickander KK, Schmelzer JD, Rohwer DA, Low PA. Effect of alpha-tocopherol deficiency on indices of oxidative stress in normal and diabetic peripheral nerve. J Neurol Sci 1994;126(1):6-14.
31. Feldman EL, Stevens MJ, Greene DA. Pathogenesis of diabetic neuropathy. Clin Neurosci 1997;4(6):365-70.
32. Ewing DJ, Campbell IW, Burt AA, Clarke BF. Vascular reflexes in diabetic autonomic neuropathy. Lancet 1973;2(7842):1354-6.
33. Campbell LV, Kraegen EW, Lazarus L. Defective blood glucose counterregulation in diabetic is a selective form of autonomic neuropathy. Br Med J 1977;2:1527-9.
34. Martyn CN, Ewing DJ. Pupil cycle time: a simple way of measuring an autonomic reflex. J Neurol Neurosurg Psychiatry 1986;49(7):771-4.
35. Ewing DJ, Campbell IW, Clarke BF. Heart rate changes in diabetes mellitus. Lancet 1981;1(8213):183-6.
36. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med 1980;69:95-108.
37. Ewing DJ, Campbell IW, Clarke BF. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. Ann Int Med 1980;92:308-11.
38. Spallone V, Maiello MR, Cicconetti E, Menzinger G. Autonomic neuropathy and cardiovascular risk factors in insulin-dependent and non insulin-dependent diabetes. Diabetes Res Clin Pract 1997;34(suppl. 3):169-79.
39. Ewing DJ, Borsey DQ, Bellavere F, Clarke BF. Cardiac autonomic neuropathy in diabetes: comparison of measures of RR interval variation. Diabetologia 1981;21(1):18-24.
40. Kennedy WR, Navarro X, Sutherland DE. Neuropathy profile of diabetic patients in a pancreas transplantation program. Neurology 1995;45(4):773-80.
41. Ziegler D, Dannehl K, Muhlen H, Spuler M, Gries FA. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy. Diabet Med 1992;9(9):806-14.
42. Glowniak JV. Cardiac studies with metaiodobenzylguanidine: a critique of methods and interpretation of results. J Nucl Med 1995;36(11):2133-7. Review.
43. Mantysaari M, Kuikka J, Mustonen J, Tahvanainen K, Vanninen E, Lansimies E, et al. Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I] metaiodobenzylguanidine. Diabetes 1992;41(9):1069-75.
44. Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in diabetes mellitus assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol 1995;25:610-8.
45. Murata K, Araki S. Assessment of autonomic neurotoxicity in occupational and environmental health as determined by ECG R-R interval variability: a review. Am J Ind Med 1996;30(2):155-63.
46. Murata K, Sumida Y, Murashima S, Matsumura K, Takeda H, Nakagawa T, et al. A novel method for the assessment of autonomic neuropathy in type 2 diabetic patients: a comparative evaluation of 123I-MIBG myocardial scintigraphy and power spectral analysis of heart rate variability. Diabet Med 1996;13(3):266-72.
47. Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M, et al. Synthesis and preliminary evaluation of carbon-11-meta- hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J Nucl Med 1990;31(8):1328-34.
48. Stevens MJ, Raffel DM, Allman KC, Dayanikli F, Ficaro E, Sandford T, et al. Cardiac sympathetic dysinnervation in diabetes implications for enhanced cardiovascular risk. Circulation 1998;98:961-8.
49. Stevens MJ, Raffel DM, Allman KC, Schwaiger M, Wieland DM. Regression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. Metabolism 1999;48:92-101.
50. O'Brien IA, McFadden JP, Corrall RJ. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med 1991;79:495-502.
51. th ed. Philadelphia: WB Saunders Co., 2005. p. 1355-66.
52. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978;1:168-88.
53. Amthor KF, Dahl-Jorgensen K, Berg TJ, Sandvik L, Hanssen KF. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo study. Diabetologia 1994;37:579-86.
54. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
55. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53.
56. Kennedy WR, Navarro X, Goetz FC, Sutherland DE, Najarian JS. Effects of pancreas transplantation on diabetic neuropathy. N Engl J Med 1990;322:1031-7.
57. Boulton AJM. Current and emerging treatments for the diabetic neuropathies. Diabetes Rev 1999;7:279-386.
58. γ-Linolenic Acid Multicenter Trial Group. Treatment of diabetic neuropathy with [gamma]-linolenic acid. Diabetes Care 1993;16:8-15.
59. Hounsom L, Horrobin DF, Tritschler H, Corder R, Tomlinson DR. A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia 1998;41:839-43.
60. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002;50:393-413.